Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trial.
about
Didanosine therapy in patients intolerant of or failing zidovudine therapyRelationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatientsPharmacokinetics of dideoxyinosine in neonatal pigtailed macaques.Quantitative relationships between zidovudine exposure and efficacy and toxicityPopulation pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.Effect of fluconazole on pharmacokinetics of 2',3'-dideoxyinosine in persons seropositive for human immunodeficiency virus.Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complexPharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsisImpact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials.Measurement of human immunodeficiency virus type 1 p24 in serum by an ultrasensitive enzyme immunoassay, the two-site immune complex transfer enzyme immunoassay.Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients.Intracellular nucleotides of (-)-2',3'-deoxy-3'-thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus.Modeling of the change in CD4 lymphocyte counts in patients before and after administration of the human immunodeficiency virus protease inhibitor indinavir.Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents.Management of antiretroviral drug therapy in human immunodeficiency virus infection.Surrogate markers for assessing treatment response in HIV disease.Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity.Pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1-infected children.
P2860
Q28327854-E67862ED-D565-4371-8AA0-4F1597BF05E7Q33692547-2AFC1663-BE01-4F5A-8A9F-CCFBDC14D271Q33752888-23481BF5-445F-4133-9993-82E93630B3D9Q33756402-B8571FC4-2AE6-4794-948A-9C2EDA9F0E71Q33980164-88CC47C3-18C0-4903-B102-0BAD4B6D7C7BQ35114198-C2B4E0CF-439E-4586-B445-C794D0D9AF4EQ35119768-43D74E61-EAC3-4017-A8B4-530AB42CC2E6Q35810298-08756970-6E39-48A1-9999-F5816F99D11EQ35862757-11524BF4-EA3C-4739-9F0A-59FC9A9C3EF6Q36518155-14456650-0C00-4318-985F-391658364841Q37245017-5B45A743-94FA-44D8-80E3-72AAF40C347CQ39471742-C227A0E7-F3CB-424A-8D3D-8A4BE3202A60Q39559492-FB3858F5-CDBC-4E84-BBB6-F8EA1F628D99Q39783700-4BF08EFA-7280-4F02-8042-1138DBC96E31Q40552884-AADD1F90-DE62-4803-9D11-476741B05D4BQ40626125-E0B2D9FA-8F7A-4008-B49F-890E2EF2FA28Q40709551-F1F5F7BF-4707-47B4-BD95-DF4E130AE45AQ44129880-31DF5728-0E5A-44E5-BF22-74FF9A2B3ADBQ45117171-D9B97405-1815-4363-B864-B7332A757AAD
P2860
Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trial.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Relationship between dideoxyin ...... us infection. A phase I trial.
@en
Relationship between dideoxyin ...... us infection. A phase I trial.
@nl
type
label
Relationship between dideoxyin ...... us infection. A phase I trial.
@en
Relationship between dideoxyin ...... us infection. A phase I trial.
@nl
prefLabel
Relationship between dideoxyin ...... us infection. A phase I trial.
@en
Relationship between dideoxyin ...... us infection. A phase I trial.
@nl
P2093
P1476
Relationship between dideoxyin ...... us infection. A phase I trial.
@en
P2093
P304
P356
10.7326/0003-4819-116-7-562
P407
P577
1992-04-01T00:00:00Z